Nexalin Gets Nasdaq Extension But Faces Bid Price and Equity Deadlines
Nexalin Technology received a Nasdaq Hearings Panel decision allowing its common stock to stay listed on The Nasdaq Capital Market, subject to conditions. The company must meet the $1.00 minimum bid price by September 28, 2026 and the $2,500,000 stockholders' equity requirement by January 4, 2027, or its stock faces delisting.
Key points
- Panel granted continued listing in a notice received September 25, 2026.
- Company must show a closing bid price of $1.00 or greater for at least 20 consecutive trading sessions.
- Stockholders' equity must meet the $2,500,000 minimum by January 4, 2027.
- Filing states there can be no assurance the company will meet the conditions.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.